Prothena’s (PRTA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Prothena (NASDAQ:PRTA) in a research note published on Friday morning,Benzinga reports. HC Wainwright currently has a $48.00 price objective on the biotechnology company’s stock. HC Wainwright also issued estimates for Prothena’s Q4 2025 earnings at ($0.58) EPS.

A number of other analysts also recently issued reports on PRTA. Oppenheimer lifted their price objective on Prothena from $58.00 to $62.00 and gave the stock an “outperform” rating in a research note on Friday, February 7th. Bank of America reduced their price target on shares of Prothena from $26.00 to $22.00 and set a “neutral” rating on the stock in a research report on Thursday, December 19th. Chardan Capital reiterated a “buy” rating and set a $40.00 price objective on shares of Prothena in a research report on Friday. Finally, StockNews.com cut Prothena from a “hold” rating to a “sell” rating in a report on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, Prothena currently has an average rating of “Moderate Buy” and an average price target of $45.83.

Prothena Stock Performance

Shares of NASDAQ:PRTA opened at $15.56 on Friday. The firm has a market cap of $837.27 million, a price-to-earnings ratio of -6.77 and a beta of 0.08. The firm has a fifty day moving average price of $14.33 and a 200 day moving average price of $16.76. Prothena has a fifty-two week low of $11.70 and a fifty-two week high of $31.03.

Prothena (NASDAQ:PRTA) last released its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.06). Prothena had a negative net margin of 90.50% and a negative return on equity of 22.67%. The company had revenue of $2.12 million for the quarter, compared to the consensus estimate of $7.53 million. As a group, research analysts predict that Prothena will post -4.04 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. Barclays PLC raised its holdings in shares of Prothena by 110.2% in the third quarter. Barclays PLC now owns 95,222 shares of the biotechnology company’s stock worth $1,592,000 after buying an additional 49,916 shares during the period. SG Americas Securities LLC raised its position in Prothena by 167.0% during the 4th quarter. SG Americas Securities LLC now owns 37,612 shares of the biotechnology company’s stock valued at $521,000 after purchasing an additional 23,525 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Prothena by 1,122.9% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 526,748 shares of the biotechnology company’s stock worth $8,812,000 after buying an additional 483,673 shares during the period. Duncan Williams Asset Management LLC grew its position in shares of Prothena by 41.9% during the 4th quarter. Duncan Williams Asset Management LLC now owns 69,199 shares of the biotechnology company’s stock worth $958,000 after buying an additional 20,450 shares in the last quarter. Finally, Focused Wealth Management Inc bought a new stake in shares of Prothena in the fourth quarter valued at about $445,000. Hedge funds and other institutional investors own 97.08% of the company’s stock.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.